Literature DB >> 1375013

Fabry disease: immunocytochemical characterization of neuronal involvement.

G A deVeber1, G A Schwarting, E H Kolodny, N W Kowall.   

Abstract

Fabry disease is an X-linked glycosphingolipid storage disease caused by deficiency of alpha-galactosidase. Storage of globotriaosylceramide, also known as ceramide trihexoside, is maximal in blood vessels but also occurs in neurons. We performed neuropathological histochemical studies on the brains and spinal cords of 2 patients with confirmed Fabry disease. Luxol fast blue-positive deposits were found in blood vessels throughout the central and peripheral nervous system and within selected neurons in spinal cord and ganglia, brainstem, amygdala, hypothalamus, and entorhinal cortex. Regions adjacent to involved neuronal groups, including nucleus basalis, striatum, globus pallidus, and thalamus, were spared. Electron microscopy showed lamellar cytoplasmic neuronal inclusion bodies. Using a monoclonal antibody reactive with ceramide trihexoside, we found more extensive neuronal deposition than evident by Luxol-fast blue staining and new areas of neuronal storage in the spinal cord and cerebral cortex. Blood vessels throughout the nervous system were strongly immunoreactive. The highly selective pattern of neuronal involvement we found suggests that glycosphingolipid exposure, uptake, or catabolism varies greatly with respect to neuronal morphology and distribution. The degree of toxicity to neurons and the clinical significance of this neuronal storage remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375013     DOI: 10.1002/ana.410310410

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

1.  Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease.

Authors:  Andreas Fellgiebel; Dominik O Wolf; Edwin Kolodny; Matthias J Müller
Journal:  J Inherit Metab Dis       Date:  2011-09-20       Impact factor: 4.982

2.  Significance of screening for Fabry disease among male dialysis patients.

Authors:  Mayuri Ichinose; Masaaki Nakayama; Toya Ohashi; Yasunori Utsunomiya; Masahisa Kobayashi; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Authors:  R Schiffmann; G J Murray; D Treco; P Daniel; M Sellos-Moura; M Myers; J M Quirk; G C Zirzow; M Borowski; K Loveday; T Anderson; F Gillespie; K L Oliver; N O Jeffries; E Doo; T J Liang; C Kreps; K Gunter; K Frei; K Crutchfield; R F Selden; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation.

Authors:  H-J Lee; S-C Hung; T-R Hsu; S-C Ko; T Chui-Mei; C-C Huang; D-M Niu; C-P Lin
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-11       Impact factor: 3.825

5.  Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

Authors:  Jin-Ok Choi; Mi Hee Lee; Hae-Young Park; Sung-Chul Jung
Journal:  J Biomed Sci       Date:  2010-04-16       Impact factor: 8.410

6.  A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier.

Authors:  M Uchino; E Uyama; H Kawano; J Hokamaki; K Kugiyama; Y Murakami; H Yasue; M Ando
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease.

Authors:  Jun-ichi Takanashi; A James Barkovich; William P Dillon; Elliott H Sherr; Kimberly A Hart; Seymour Packman
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

8.  Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease.

Authors:  M Inagaki; T Katsumoto; E Nanba; K Ohno; S Suehiro; K Takeshita
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 9.  Pathogenic cascades in lysosomal disease-Why so complex?

Authors:  S U Walkley
Journal:  J Inherit Metab Dis       Date:  2009-01-07       Impact factor: 4.982

10.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.